Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishal Navani

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Current Oncology (Toronto, Ont.)|July 26, 2024
What Is Ailing Oncology Clinical Trials? Can We Fix Them?Abhenil Mittal, Sara Moore, Vishal Navani, et al.
Frontiers in Oncology|June 17, 2024
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort studyMehul Gupta, Igor Stukalin, Daniel E Meyers, et al.
Pharmacology Research & Perspectives|June 15, 2021
Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markersVishal Navani, Moira C Graves, Giovana Celli Marchett, et al.
Cancer Treatment and Research|May 13, 2022
Melanoma: An immunotherapy journey from bench to bedsideVishal Navani, Moira C Graves, Hiren Mandaliya, et al.
JAMA Network Open|June 23, 2023
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced MelanomaMehul Gupta, Igor Stukalin, Daniel Meyers, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian expertsJenny J Ko, Normand Blais, Anthony Brade, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2026
A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary siteJose G Monzon, Hatim Karachiwala, John Walker, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in AlbertaWinson Y Cheung, Chantelle Carbonell, Vishal Navani, et al.
JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Asia-Pacific Journal of Clinical Oncology|March 31, 2026
Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center CohortHeather Halperin, Amanda J W Gibson, Ali Hussein, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Current Oncology (Toronto, Ont.)|July 26, 2024
What Is Ailing Oncology Clinical Trials? Can We Fix Them?Abhenil Mittal, Sara Moore, Vishal Navani, et al.
Frontiers in Oncology|June 17, 2024
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort studyMehul Gupta, Igor Stukalin, Daniel E Meyers, et al.
Pharmacology Research & Perspectives|June 15, 2021
Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markersVishal Navani, Moira C Graves, Giovana Celli Marchett, et al.
Cancer Treatment and Research|May 13, 2022
Melanoma: An immunotherapy journey from bench to bedsideVishal Navani, Moira C Graves, Hiren Mandaliya, et al.
JAMA Network Open|June 23, 2023
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced MelanomaMehul Gupta, Igor Stukalin, Daniel Meyers, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian expertsJenny J Ko, Normand Blais, Anthony Brade, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2026
A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary siteJose G Monzon, Hatim Karachiwala, John Walker, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in AlbertaWinson Y Cheung, Chantelle Carbonell, Vishal Navani, et al.
JAMA Network Open|January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint InhibitorsSarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Asia-Pacific Journal of Clinical Oncology|March 31, 2026
Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center CohortHeather Halperin, Amanda J W Gibson, Ali Hussein, et al.
Pageof 4